SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-000275
Filing Date
2022-01-14
Accepted
2022-01-14 17:00:23
Documents
18
Period of Report
2022-01-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20220112x8k.htm   iXBRL 8-K 59584
2 EX-10.1 acrs-20220112xex10d1.htm EX-10.1 120172
3 EX-10.2 acrs-20220112xex10d2.htm EX-10.2 116423
4 GRAPHIC acrs-20220112xex10d1001.jpg GRAPHIC 715
5 GRAPHIC acrs-20220112xex10d1002.jpg GRAPHIC 747
6 GRAPHIC acrs-20220112xex10d2002.jpg GRAPHIC 747
7 GRAPHIC acrs-20220112xex10d2001.jpg GRAPHIC 715
  Complete submission text file 0001558370-22-000275.txt   474239

Data Files

Seq Description Document Type Size
8 EX-101.SCH acrs-20220112.xsd EX-101.SCH 2984
9 EX-101.LAB acrs-20220112_lab.xml EX-101.LAB 16066
10 EX-101.PRE acrs-20220112_pre.xml EX-101.PRE 10373
12 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20220112x8k_htm.xml XML 4846
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 22532508
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences